ANI Pharmaceuticals Inc (ANIP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.37 Million) by net assets ($540.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANIP market cap for the company's overall valuation and market capitalisation.
ANI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ANI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of ANI Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tamilnad Mercantile Bank Limited
NSE:TMB
|
-0.323x |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
-0.079x |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
-0.002x |
|
Skywater Technology Inc
NASDAQ:SKYT
|
-0.028x |
|
Yantai Tayho Advanced Materials Co Ltd
SHE:002254
|
0.045x |
|
Galapagos NV
F:GXEA
|
-0.025x |
|
Generation Capital Ltd
TA:GNRS
|
0.046x |
|
Yantai Zhenghai Magnetic Mat
SHE:300224
|
0.015x |
Annual Cash Flow Conversion Efficiency for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of ANI Pharmaceuticals Inc from 1998 to 2025. View today's stock price for ANI Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $540.72 Million | $185.22 Million | 0.343x | +129.30% |
| 2024-12-31 | $428.53 Million | $64.02 Million | 0.149x | -42.54% |
| 2023-12-31 | $457.60 Million | $118.96 Million | 0.260x | +382.05% |
| 2022-12-31 | $338.54 Million | $-31.20 Million | -0.092x | -1095.33% |
| 2021-12-31 | $358.74 Million | $3.32 Million | 0.009x | -88.13% |
| 2020-12-31 | $195.70 Million | $15.27 Million | 0.078x | -63.62% |
| 2019-12-31 | $212.79 Million | $45.63 Million | 0.214x | -36.93% |
| 2018-12-31 | $197.26 Million | $67.07 Million | 0.340x | +50.74% |
| 2017-12-31 | $174.76 Million | $39.42 Million | 0.226x | +39.29% |
| 2016-12-31 | $169.65 Million | $27.47 Million | 0.162x | +50.16% |
| 2015-12-31 | $160.08 Million | $17.26 Million | 0.108x | -31.58% |
| 2014-12-31 | $139.78 Million | $22.03 Million | 0.158x | +217.73% |
| 2013-12-31 | $40.96 Million | $-5.48 Million | -0.134x | +85.08% |
| 2012-12-31 | $28.18 Million | $-25.28 Million | -0.897x | +29.11% |
| 2011-12-31 | $37.82 Million | $-47.87 Million | -1.266x | +39.55% |
| 2010-12-31 | $19.15 Million | $-40.10 Million | -2.094x | -79.87% |
| 2009-12-31 | $15.83 Million | $-18.43 Million | -1.164x | -3.62% |
| 2008-12-31 | $13.83 Million | $-15.54 Million | -1.124x | -4613.67% |
| 2007-12-31 | $29.73 Million | $739.99K | 0.025x | +109.00% |
| 2006-12-31 | $18.07 Million | $-5.00 Million | -0.277x | +77.28% |
| 2005-12-31 | $6.82 Million | $-8.30 Million | -1.217x | -85.52% |
| 2004-12-31 | $15.92 Million | $-10.44 Million | -0.656x | -3.15% |
| 2003-12-31 | $8.68 Million | $-5.52 Million | -0.636x | +25.81% |
| 2002-12-31 | $4.62 Million | $-3.96 Million | -0.857x | -90.38% |
| 2001-12-31 | $4.05 Million | $-1.82 Million | -0.450x | +70.17% |
| 2000-12-31 | $2.13 Million | $-3.21 Million | -1.509x | -360.05% |
| 1999-12-31 | $5.45 Million | $-1.79 Million | -0.328x | +71.62% |
| 1998-12-31 | $2.63 Million | $-3.04 Million | -1.156x | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more